Supplementary materials for “First report of severe acute graft versus host disease after allogeneic stem cell transplant in a patient with myelodysplastic syndrome treated with atezolizumab: literature review”

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Study | N | Median FU (months) | CPI | Median Cycles | Time Between Last Dose and Transplant(days) | GVHD ppx | Acute GVHD (%) | Chronic GVHD (%) | Deaths (%) | GVHD-related Deaths (%) |
| Kasamon et al. 2017 1 | 17 | 4.6 | nivolumab | 9 | 28 | NA | 65 | NA | 35 | 83 |
| Merryman et al. 2017 2 | 39 | 12 | Nivolumabpembrolizumab | 8 | 62 | Multiple agents | 44 | 41 | 10 | 75 |
| Beköz et al. 2017 3 | 11 | 2 | Nivolumab | 9 | 30 | NA | 36 | 9 | 18 | 50 |
| Schoch et al. 2016 4 | 11 | 8 | Nivolumabipilimumab | 4 | 43 | NA | 36 | 0 | 0 | 0 |
| Armand et al. 2016 5 | 17 | 8.7 | nivolumab | 9 | 29 | NA | 82 | NA | 35 | 100 |
| Covut et al. 2017 6 | 3 | 4.7 | nivolumab | 11 | NA | Tacro/MMFCytoxan/tacro/MMF | 33 | NA | 33 | 0 |
| El Cheikh et al. 2017 7 | 9 | 10 | nivolumab | 8 | 44 | ATG/Cyclosporine/MMF | 100 | 33 | 11 | 100 |

Table 1. A summary of abstracts and studiesthat have evaluated checkpoint inhibitors prior to allogeneic hematopoietic stem cell transplant.

References:

1. Kasamon YL, de Claro RA, Wang Y, Shen YL, Farrell AT, and Pazdur R. FDA approval summary: nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma. *Oncologist*. 2017; 22: 585–591
2. Merryman RW, Kim HT, Zinzani PL, Carlo-Stella C, Ansell SM, Perales MA, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. *Blood*. 2017; 129(10): 1380-1388.
3. Beköz H, Karadurmuş N, Paydaş S, Turker A, Toptas T, Firatli Tuglular T, et al. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. *Ann Oncol*. 2017; 28:2496–2502
4. Schoch LK, Borrello I, Fuchs EJ, Bolanos-Meade J, Huo JS, Gojo I, et al. Checkpoint inhibitor therapy and graft versus host disease in allogeneic bone marrow transplant recipients of haploidentical and matched products with post-transplant cyclophosphamide. *Blood*. 2016; 128(22):4571.
5. Armand P, Zinzani PL, Collins GP, Cohen JB, Halwani AS, Carlo-Stella C, et al. Outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) after treatment with nivolumab for relapsed/refractory Hodgkin lymphoma. *Blood*. 2016; 128(22): 3502
6. Covut F, Pinto R, Cooper BW, Tomlinson B, Metheny L, Malek E, et al. Nivolumab before and after allogeneic hematopoietic cell transplantation. *Bone Marrow Transplant*. 2017; 52:1054–1056
7. El Cheikh J, Massoud R., Abudalle I, Haffar B, Mahfouz R, Kharfan-Dabaja MA, et al. Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma. *Bone Marrow Transplant*. 2017; 52:1074–1077.